KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Operating Expenses: 2011-2025

Historic Operating Expenses for Travere Therapeutics (TVTX) over the last 15 years, with Sep 2025 value amounting to $139.9 million.

  • Travere Therapeutics' Operating Expenses rose 17.54% to $139.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $527.0 million, marking a year-over-year decrease of 6.03%. This contributed to the annual value of $557.0 million for FY2024, which is 4.43% up from last year.
  • Travere Therapeutics' Operating Expenses amounted to $139.9 million in Q3 2025, which was up 10.09% from $127.1 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Operating Expenses high stood at $180.6 million for Q1 2024, and its period low was $46.4 million during Q4 2021.
  • Its 3-year average for Operating Expenses is $134.7 million, with a median of $129.7 million in 2023.
  • As far as peak fluctuations go, Travere Therapeutics' Operating Expenses slumped by 72.60% in 2021, and later soared by 149.85% in 2022.
  • Over the past 5 years, Travere Therapeutics' Operating Expenses (Quarterly) stood at $46.4 million in 2021, then surged by 149.85% to $116.0 million in 2022, then rose by 20.04% to $139.3 million in 2023, then dropped by 2.71% to $135.5 million in 2024, then rose by 17.54% to $139.9 million in 2025.
  • Its Operating Expenses was $139.9 million in Q3 2025, compared to $127.1 million in Q2 2025 and $124.4 million in Q1 2025.